Exagen Q3 2026 earnings

XGN · 2026-11-10 07:33 BMO ET · 8-K on SEC · 10-Q on SEC

Revenue grew 7% to $18.4 million, net loss narrowed 12% and adjusted EBITDA loss improved over 30%.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$18.4M+7%-7.5%Ex. 99.1, income statement
EPS (GAAP)-$0.25+20%-92%Ex. 99.1, income statement
EPS (adjusted)-$0.25+67%-92%Ex. 99.1, income statement
Net income-$6.3M-11%-92%Ex. 99.1, income statement
Adj. EBITDA-$1.9M+2%-69%Ex. 99.1, income statement
Adj. EBITDA margin-10.5%+1.6 pp-4.4 ppEx. 99.1, income statement

Revenue breakdown

not stated in the 8-K

Margins and costs

  • Gross margin 58.8% (prior 58.4%, change +0.4 pp)
  • Operating expenses $15.2M (+15.6% YoY)
  • One-offs in the quarter In-process R&D $0.6M; Warrant liability fair value change $0.9M
  • Effective tax rate 0% (prior-year 0%, year-to-date 0%)
  • Non-GAAP bridge Adds back interest, tax, depreciation, stock-based comp, warrant liability fair value, and in-process R&D.

KPIs

MetricActualPrior quarterPrior yearChange
Trailing-twelve-month ASP$451$446$441+$5
Cash and cash equivalents$28.1M$24.6M$35.7M+$3.5M

Guidance

MetricGuidePrior guideChange
Full-year revenue$72M - $75M$72M - $75MNo change

What drove it

  • Revenue story Revenue grew 7% YoY to $18.4M, but declined 7.5% QoQ.
  • EPS story EPS improved YoY due to lower net loss and share count, but widened QoQ due to higher expenses.
  • One-off check In-process R&D charge of $587,000 related to AI platform acquisition.

The good

  • Revenue grew 7% YoY
  • Adjusted EBITDA loss improved over 30% YoY
  • Cash balance increased to $28.1M
  • ASP increased to $451 (14th consecutive quarter of growth)

The bad

  • Revenue declined 7.5% QoQ
  • Net loss widened QoQ
  • Adjusted EBITDA margin declined QoQ
  • Operating expenses increased 15.6% YoY

The ugly

  • none

Open questions

  • What caused the 7.5% sequential revenue decline?
  • Why did operating expenses increase 15.6% YoY?
Full release

Exagen (XGN) earnings release, November 10, 2026

Exagen Inc. (XGN) · Form 8-K, Item 2.02 · Filed · SEC filing

Exagen Inc. Reports Third Quarter 2026 Financial Results

Third Quarter Revenue Grew 7% to $18.4 Million

Year-to-Date Revenue Grew 11%, Net Loss Reduced by 12% and Adjusted EBITDA Loss Improved by Over 30%

November 10, 2026

Carlsbad, Calif., – Exagen Inc. (Nasdaq: XGN), a precision medicine company bringing clarity to autoimmune disease, today reported financial results for the quarter ended September 30, 2026, and recent corporate updates.

Third Quarter 2026 and Recent Corporate Highlights:

• Achieved total revenue of $18.4 million, an increase of 7% compared to third quarter 2025.

• Expanded AVISE CTD trailing twelve-month ASP to $451 per test, an increase of $10 per test compared to third quarter 2025 and the 14 th consecutive quarter of growth.

• Ended the quarter with approximately $28.1 million in cash and cash equivalents.

• Presented nine abstracts at the 2026 American College of Rheumatology (ACR) Convergence Conference, including two podium presentations on proprietary T-cell marker disease associations and an analysis of phenotypic patterns across more than 375,000 AVISE CTD tests.

“Our third quarter extends what is fast becoming a record year for Exagen, and our ability to execute against our vision is increasingly evident in the results. The team grew the business again, with test volume and ASP both ahead of the same period last year,” said John Aballi, President and Chief Executive Officer of Exagen. “Beyond our financial performance, our strong showing at ACR Convergence demonstrates that our science continues to push the boundaries of traditional autoimmune care. We also remain on track to launch our myositis offering early in 2027, bringing greater clarity and confidence to clinicians and patients in an area of significant need.”¹

Exagen Forward: Building the Autoimmune Platform

The company will host an educational webcast on December 15, 2026, at 12:00 p.m. ET (9:00 a.m. PT) to discuss the significant unmet clinical need in myositis, Exagen’s unique myositis solution, and additional pipeline development efforts. Further details, including registration information, will be provided at a later date.

2026 Guidance

The company reiterated full-year 2026 revenue guidance of $72 million to $75 million.

Conference Call and Webcast

John Aballi, President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a webcast at 8:00 a.m. ET (5:00 a.m. PT) this morning to review the results.

The webcast will be available on the Exagen Investor Relations website at investors.exagen.com. Participants wishing to join by phone should register in advance using the following link for dial-in instructions: https://register-conf.media-server.com/register/BId7f4a0dc53154d5e84d4eb39ccfa279d.

A replay of the webcast will be available for 12 months via the Exagen Investor Relations website at investors.exagen.com

Use of Non-GAAP Financial Measures (Unaudited)

In addition to the financial results prepared in accordance with generally accepted accounting principles in the United States (GAAP), this press release contains the metric adjusted EBITDA, which is not calculated in accordance with GAAP and is a non-GAAP financial measure. Adjusted EBITDA is defined as net loss adjusted for other income (expense), net, interest income (expense), income tax expense (benefit), depreciation and amortization expense, stock‑based compensation expense, change in fair value of warrant liability, acquired in-process research and development, and certain other non‑cash, unusual or non‑recurring items, including, for example, losses on extinguishment of debt; we do not exclude normal, recurring, cash operating expenses from this measure. Such items could have a significant impact on the calculation of GAAP net loss.

Exagen uses adjusted EBITDA internally because the company believes this measure provides useful supplemental information in addition to its operating performance reported in accordance with GAAP. Exagen believes adjusted EBITDA may enhance an evaluation of the operating performance because it excludes the impact of prior decisions made about capital investment, financing, investing and certain expenses the company believes are not indicative of the ongoing performance. However, this non-GAAP financial measure may be different from non-GAAP financial measures used by other companies, even when the same or similarly titled terms are used to identify such measures, limiting their usefulness for comparative purposes.

This non-GAAP financial measure is not meant to be considered in isolation or used as a substitute for net loss reported in accordance with GAAP, should be considered in conjunction with the financial information presented in accordance with GAAP, has no standardized meaning prescribed by GAAP, is unaudited, and is not prepared under any comprehensive set of accounting rules or principles. In addition, from time to time in the future, there may be other items that Exagen may exclude for purposes of these non-GAAP financial measures, and the company may in the future cease to exclude items that it has historically excluded for purposes of these non-GAAP financial measures. Likewise, Exagen may determine to modify the nature of adjustments to arrive at these non-GAAP² financial measures. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measure as used by the company in this press release and the accompanying reconciliation table have limits in their usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. Accordingly, investors should not place undue reliance on non-GAAP financial measures.

A reconciliation of net loss to non-GAAP adjusted EBITDA is provided in the financial schedules that are part of this press release.

About Exagen... (truncated)pany with an autoimmune platform that empowers physicians to make more confident decisions, earlier. Its flagship test, AVISE®

CTD, provides diagnostic clarity in complex autoimmune conditions such as lupus, rheumatoid arthritis, and Sjögren's disease. Based in San Diego County, California, Exagen operates a CLIA-certified, CAP-accredited rheumatology laboratory delivering precise, timely results to physicians and partners across healthcare and biopharma. Through ongoing research and innovation, Exagen is committed to advancing care for autoimmune disease.

For more information, visit Exagen.com or follow Exagen on LinkedIn.

Financial statements

Income Statement

Three Months Ended September 30, (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Unaudited. In thousands, except ASP data.
Revenue18,41717,24455,66449,944
Gross margin58.8%58.4%59.7%59.3%
Operating expenses15,24413,17542,80238,688
Operating loss-4,408-3,100-9,544-9,095
Net loss-6,336-7,087-13,499-15,278
Adjusted EBITDA-1,932-1,895-4,206-6,124
Trailing-twelve-month average selling price (ASP)451441451441
Cash and cash equivalents (as of September 30)28,09235,65228,09235,652

Income Statement

Three Months Ended September 30, — (in thousands, except share and per share amounts)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenue18,41717,24455,66449,944
Cost of revenue7,5817,16922,40620,351
Gross profit10,83610,07533,25829,593
Operating expenses:
Selling, general and administrative expenses12,83411,44537,41334,191
Research and development expenses1,8231,7304,8024,497
In-process research and development expenses*587587
Total operating expenses15,24413,17542,80238,688
Loss from operations-4,408-3,100-9,544-9,095
Interest expense-1,201-1,319-3,669-2,988
Loss on extinguishment of debt-295
Change in fair value of warrant liability-909-2,670-453-3,108
Other income (expense), net1813202246
Loss before income taxes-6,337-7,086-13,464-15,240
Income tax (expense) benefit1-1-35-38
Net loss-6,336-7,087-13,499-15,278
Net loss per share, basic and diluted-0.25-0.31-0.56-0.73
Weighted-average number of shares used to compute net loss per share, basic and diluted24,849,79722,940,41224,294,83920,878,373

Income Statement

Three Months Ended September 30, (in thousands)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net loss-6,336-7,087-13,499-15,278
Other (income) expense, net-181-3-202-246
Interest expense1,2011,3193,6692,988
Loss on extinguishment of debt295
Change in fair value of warrant liability9092,6704533,108
Income tax expense (benefit)-113538
Depreciation and amortization expense6506121,8771,518
Stock-based compensation expense1,2395932,8741,453
In-process research and development expense587587
Adjusted EBITDA (Non-GAAP)-1,932-1,895-4,206-6,124

Balance Sheet

September 30, 2026 — (in thousands, except share and per share amounts)

September 30, 2026December 31, 2025
Current assets:
Cash and cash equivalents28,09232,220
Accounts receivable, net11,48110,855
Prepaid expenses and other current assets5,7595,818
Total current assets45,33248,893
Property and equipment, net6,0586,938
Operating lease right-of-use assets3,3561,435
Other assets607756
Total assets55,35358,022
Current liabilities:
Accounts payable3,7474,153
Accrued and other current liabilities5,5706,327
Deferred revenue1,398675
Finance lease liabilities, current1,0621,135
Operating lease liabilities, current8701,226
Borrowings, current453643
Total current liabilities13,10014,159
Borrowings, non-current, net of discounts and debt issuance costs22,35922,264
Finance lease liabilities, non-current1,4391,960
Operating lease liabilities, non-current2,578438
Warrant liability2,1021,752
Total liabilities41,57840,573
Stockholders' equity:
Common stock, $0.001 par value; 200,000,000 shares authorized as of September 30, 2026 and December 31, 2025; 25,420,340 and 22,911,575 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively2523
Additional paid-in capital341,531331,708
Accumulated deficit-327,781-314,282
Total stockholders' equity13,77517,449
Total liabilities and stockholders' equity55,35358,022

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (in thousands)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Cash flows from operating activities:
Net loss-13,499-15,278
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization1,8771,518
Amortization of debt discount and debt issuance costs420247
Amortization of loan commitment fees1,019461
Change in fair value of warrant liability4533,108
Loss on extinguishment of debt295
Non-cash operating lease expense690717
Stock-based compensation2,8741,453
Other-17147
Changes in assets and liabilities:
Accounts receivable, net-626-3,257
Prepaid expenses and other current assets-9611,358
Other assets149494
Operating lease liabilities-828-808
Accounts payable-439-545
Deferred revenue723-92
Accrued and other current liabilities-839-430
Net cash used in operating activities-9,004-10,612
Cash flows from investing activities:
Purchases of property and equipment-967-597
Proceeds from disposal of property and equipment6
Net cash used in investing activities-967-591
Cash flows from financing activities:
Proceeds from common stock issued, net of issuance costs18,627

Forward-Looking Statements

Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. Words such as “anticipate,” “believe,” “expect,” “guidance,” “intend,” “may,” “on track,” “plan,” “will” and similar expressions are intended to identify forward-looking statements. These statements are based on Exagen’s current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: Exagen’s goals, strategies, positioning and ambitions; evaluations and judgments regarding financial results and the potential implications of those results; potential future financial and business performance, including any improvements to adjusted EBITDA, ASP, net loss and potential profitability; the potential utility and effectiveness of Exagen’s services and testing solutions; the timing of Exagen’s myositis and pipeline development; the impact of Exagen’s revenue cycle management strategy on the timing of collections and cash burn; potential stockholder value and growth; and full-year 2026 revenue guidance. The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Exagen’s business, including, without limitation: delays in reimbursement and coverage decisions from Medicare and third-party payors and interactions with regulatory authorities, and delays in ongoing and planned clinical trials involving its tests; the potential effects of inflation and tariffs on Exagen’s margins; changes in laws and regulations related to Exagen’s regulatory requirements; fluctuations in the fair value of its warrant liability; Exagen’s commercial success, which depends upon attaining and maintaining significant market acceptance of its testing products among rheumatologists, patients, third-party payors and others in the medical community; Exagen’s ability to successfully execute on its business strategies; Exagen’s ability to obtain additional funding; third-party payors not providing coverage and adequate reimbursement for Exagen’s testing products, including Exagen’s ability to collect on funds due; Exagen’s ability to obtain and maintain intellectual property protection for its testing products; regulatory developments affecting Exagen’s business; and other risks described in Exagen’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in Exagen’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 10, 2026, its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2026, June 30, 2026, and September 30, 2026, filed with the SEC May 11, 2026, August 4, 2026, and November 10, 2026, and any subsequent filings with the SEC.³

You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Exagen undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.

Investors:

Tina Jacobsen, CFA

Exagen Inc. ir@exagen.com⁴

Exagen Inc.

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)

*

On July 16, 2026, the Company acquired certain assets including the rights to technology, software, source code, know-how and patents comprising an AI-enabled rheumatology practice workflow-optimization software platform. The transaction was accounted for as an asset acquisition. The Company recognized an in-process research and development (IPR&D) charge of $587,000 related to the transaction.⁵

Exagen Inc.

Unaudited Condensed Consolidated Balance Sheets

(in thousands, except share and per share amounts)⁶

Exagen Inc.

Reconciliation of Non-GAAP Financial Measures (UNAUDITED)

The table below presents the reconciliation of adjusted EBITDA, which is a non-GAAP financial measure. See "Use of Non-GAAP Financial Measures (UNAUDITED)" above for further information regarding Exagen's use of non-GAAP financial measures.⁷

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Exagen earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.